<DOC>
	<DOCNO>NCT02732236</DOCNO>
	<brief_summary>Marginal zone lymphoma rare subtype Non-Hodgkin Lymphoma . Because rarity , prospective clinical trial difficult conduct . Therefore want make prospective MZL patient ' cohort several observation study</brief_summary>
	<brief_title>Marginal Zone Lymphoma Cohort Korea</brief_title>
	<detailed_description>Marginal zone lymphoma ( MZL ) distinct subgroup non-Hodgkin 's lymphoma ( NHL ) , typically characterized indolent clinical course long survival duration . MZL responsible approximately 7~8 % NHL . In Korea , MZL account 21 % B-cell lymphoma second frequent histologic subtype follow diffuse large B-cell lymphoma . Annually , estimate 500 patient newly diagnose MZL . According previous large-scale analysis , MZL usually quiet indolent malignancy , generally present limited stage disease . Localized disease may control local treatment , high response rate achieve . Advanced MZL associate less favorable survival , appear incurable currently available therapy . Transformation large cell aggressive lymphoma may occur first recurrence subsequent relapse . Because rarity , prospective clinical trial difficult conduct . Therefore want make prospective MZL patient ' cohort several observation study especially related Rituximab use ( ex , Hepatitis B virus ( HBV ) reactivation )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>pathological confirm marginal zone lymphoma No history chemotherapy enable routine staging w/u sample include HBV serology inform consent mixed type lymphoma refuse inform consent coexist cancer need treatment prior organ transplantation accompany immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>Cohort</keyword>
	<keyword>Rituximab</keyword>
	<keyword>HBV</keyword>
</DOC>